Now this is a step up for you. Not only do you rewrite history,...

First 514 Last

Share
Profile

Follow
Bazsa

3,951 Posts.

1352

06/08/24

17:40

Post #: 75096688
Share

Originally posted by whytee: ↑

"where does it say that the adult trial has to be completed for the pediatric GVHD to be approved?"

That is precisely what the FDA recommended in the first CRL. SI said they would rather complain than do it. The company told investors it was really 'just a problem with the potency assay' and after a couple of years they had a "validated" potency assay and resubmitted the BLA. SI told investors that the only outstanding thing was "a discussion on the specifics of the labelling". He was clearly not on the same wavelength as the FDA again.

Instead we get some weasel worded announcement that the FDA "acknowledged that the potency assay had been improved". The word "acknowledged" is interesting. It indicates some kind of response to a question from the company. It wasn't a spontaneous statement from the FDA. They also didn't say the treatment is efficacious in the second CRL. The company started making statements that if the FDA didn't say it WASN'T efficacious then the FDA obviously accepted that it was. Which isn't necessarily true. It simply wasn't addressed.

Now we are getting other weasel worded statements about how the FDA "acknowledged twice... that it was an adequate and well conducted trial". Once again the FDA didn't spontaneously make that comment. It was some sort of a response to a phrase used by MSB representatives. It looks like they are playing word games to try and and trap the teacher into giving a "pass" to an essay that's been marked as a "fail", and at the same time give investors some false hope to hang on to to support the company's approach and the share price.

It isn't going to work. The endless arguing about the CRL isn't going to change the outcome. The teacher said the essay is fundamentally flawed, please go away and do it again properly in accordance with the clear instructions. Now SI says they were always going to do it but he still wants to go on arguing about the second "fail" mark for the resubmitted essay.

The company's statements have been repeatedly wrong and misleading, from timelines to expectations of trial results to partnerships. I can't think of a single time SI has said something that turned out to be accurate, with the exception of the BoD's remuneration.

And yet despite being sued for misleading investors, they still accept his words as gold.
The FDA is going to say, well Osiris did randomised controlled clinical trials, so can you. Stop making excuses, that's what we want.

Expand

Now this is a step up for you.
Not only do you rewrite history, you make excuses for the FDA.
Who too believe?
I put my money on the experts . 9-1 FDA select panel.
And who was it that said the data was compelling?
Did I see another use the word " cure "

We have Docnot and we have Whylie

MSB Price at posting: 90.5¢ Sentiment: Buy Disclosure: Held
5 Upvote

3 Great analysis

Reply

Top Stories

SKC

SkyCity jumps 2% after copping A$3.6M fine from NZ High Court – far below AUSTRAC's fine

LGM

Legacy hits high-grade gold, silver and copper through drilling at NSW's Bauloora

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

QXR

QX Resources increases US lithium footprint with key agreements

QML

QMines jumps +4.6% on drill hits boasting high copper grades

First 514 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.09		Change 0.060(5.83%)		Mkt cap ! $1.244B

Open	High	Low	Value	Volume
$1.04	$1.10	$1.03	$4.925M	4.571M

Buyers (Bids)

No.	Vol.	Price($)
1	7260	$1.09

Sellers (Offers)

Price($)	Vol.	No.
$1.10	67541	7

View Market Depth

No.	Vol.	Price($)
1	7260	1.090
1	25000	1.085
5	82706	1.080
3	70397	1.075
5	96320	1.070

Price($)	Vol.	No.
1.095	67541	7
1.100	660901	37
1.105	27523	3
1.110	173120	11
1.115	55278	5

Last trade - 16.10pm 26/09/2024 (20 minute delay)

MSB (ASX) Chart

Now this is a step up for you. Not only do you rewrite history,...

SkyCity jumps 2% after copping A$3.6M fine from NZ High Court – far below AUSTRAC's fine

Legacy hits high-grade gold, silver and copper through drilling at NSW's Bauloora

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

QX Resources increases US lithium footprint with key agreements

QMines jumps +4.6% on drill hits boasting high copper grades

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Now this is a step up for you. Not only do you rewrite history,...

Top Stories

SkyCity jumps 2% after copping A$3.6M fine from NZ High Court – far below AUSTRAC's fine

Legacy hits high-grade gold, silver and copper through drilling at NSW's Bauloora

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

QX Resources increases US lithium footprint with key agreements

QMines jumps +4.6% on drill hits boasting high copper grades

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News